BlueAdmin, Author at Orlucent

News

Orlucent® Supports Research on Updated Criteria for Histopathologic Scoring and Grading of Melanocytic Dysplasia

November 4, 2024

Orlucent® Proof of Concept Activity Image Featured in Cover Story of Pigment Cell & Melanoma Research

May 8, 2024

Orlucent® Featured in Clinical Lab Products Magazine

February 14, 2024

Orlucent® Demonstrates Accurate, Non-Invasive Detection In Vivo of Melanoma-Related Activity Using First-in-Kind Handheld Imaging System

January 16, 2024

Discovery of Distinctive Set of Gene Expression Patterns Changes Understanding of Atypical Mole Development and Early Melanoma

June 22, 2023

Orlucent® Receives FDA Breakthrough Device Designation for Handheld Mole Imaging System

May 25, 2023

Registered Trademark Granted to Orlucent®

January 23, 2023

AMA Issues Category III CPT Code for Fluorescent Molecular Imaging

May 9, 2021

Orlucent® Receives California Food and Drug Branch Manufacturing License

March 11, 2021

Orlucent® Achieves ISO 13485 Certification

December 11, 2020

Clinical Trials

Bluedot - Brand & Digital

Currently in Clinical Trials. Research Use Only in the US.

©2025 Orlucent, Inc.